secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001157523-22-000536
Event type: earnings
Sentiment:  negative
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q1 GAAP loss $0.86/share; revenue down 8%; cuts FY revenue guidance
------------------------------------------------------------------------

- GAAP diluted loss per share $0.86 vs. income $0.07 in Q1 2021; non-GAAP EPS $0.55 vs. $0.63.
- Revenue $3.66B, down 8% YoY (5% local currency); FY 2022 revenue guidance lowered to $15.4-$16.0B.
- GAAP operating loss $713M driven by $1.1B opioid litigation settlement provisions.
- COPAXONE revenue outlook cut to ~$750M from ~$850M; adjusted EBITDA and EPS guidance reaffirmed.
- First generic Revlimid launched in US; AJOVY and AUSTEDO growing; opioid settlements with Florida and Rhode Island.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752322000536/0001157523-22-000536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752322000536/a52704380.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-000536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer